This article is more than 5 years old. Information may no longer be current.
Generic loteprednol etabonate approval tops OSN’s news of the week
Here are some top stories on Healio.com/OSN in the past week:
FDA approves generic loteprednol etabonate from Akorn
The FDA has approved an abbreviated new drug application for Akorn’s loteprednol etabonate ophthalmic suspension 0.5%. Read more.
Ophthalmologists push for better access to care in annual Capitol Hill visit
In an effort to lobby for better access to care, discuss important issues with lawmakers and increase education, more than 400 ophthalmologists traveled to Washington recently for the American Academy of Ophthalmology’s annual Capitol Hill visit. Read more.
Research shows microglia may control neuroinflammation
Researchers described in a press release the role of microglia in directing the initiation of autoimmune uveitis by orchestrating the inflammatory response in the retina. The research is published in Proceedings of the National Academy of Sciences. Read more.
Allegro introduces dry eye treatment candidate
The topical agent is under evaluation in a phase 2 study outside of the U.S. and is the company’s first exploratory drug not in the retina space. Read more.
Aerie aims multi-kinase inhibitor at retinal disease
The FDA has accepted Aerie Pharmaceuticals’ investigational new drug application for the AR-13503 implant, the company’s treatment candidate for neovascular age-related macular degeneration and diabetic macular edema. Read more.